FDA Issues Complete Response Letter for Lead ADHD Drug CTx-1301
CING sits 20% above its 52-week low of $3.16 on elevated volume (3.7× avg).
Summary
Cingulate Inc. received a Complete Response Letter from the FDA for its lead ADHD drug, CTx-1301, citing manufacturing and controls issues, which delays the drug's approval and commercialization.
Key Events · Product Development and Regulatory · CING
-
FDA Issues CRL for CTx-1301
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of CTx-1301, Cingulate's lead ADHD drug candidate.
-
CMC Issues Cited
The CRL primarily focused on Chemistry, Manufacturing, and Controls (CMC) information requests, with no current concerns raised regarding clinical safety or efficacy.
-
Approval Delayed
This decision delays the potential approval and commercialization of CTx-1301, requiring a resubmission of requested information to the FDA.
-
Cash Runway
Cingulate stated it has nearly $30 million in cash reserves, which it believes is sufficient to address the issues and continue pre-commercial activities into early 2027.
Analysis · CING · Life Sciences
The FDA's Complete Response Letter (CRL) for Cingulate's lead ADHD drug candidate, CTx-1301, is a significant setback, delaying potential market entry and revenue generation. While the CRL primarily cites Chemistry, Manufacturing, and Controls (CMC) issues rather than clinical safety or efficacy, it still requires a resubmission and further review, extending the timeline for approval. This event is critical for a company that previously disclosed a "going concern" warning and relies heavily on this product for its future. The company's stated cash reserves of nearly $30 million are crucial to fund the resubmission process and ongoing operations.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 41.1% of the 387 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.8M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.